Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 96
- Registration Number
- NCT04661137
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 160
- Registration Number
- NCT04656951
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 54
- Registration Number
- NCT04649060
- Locations
- 🇵🇱
Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department, Kraków, Poland
🇧🇬Specialized Hospital for Active Treatment of Hematological Diseases, Clinical Hematology Clinic, Sofia, Bulgaria
🇨🇿University Hospital Hradec Kralove, 4th Internal Clinic of Hematology, Kralovice, Czechia
Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 28
- Registration Number
- NCT04635189
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
FT538 in Subjects With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT04614636
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 228
- Registration Number
- NCT04586426
- Locations
- 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study of Health-Related Quality of Life in People with Multiple Myeloma Receiving Daratumumab or Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04497961
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04474938
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04304144
- Locations
- 🇺🇸
Clinical Trial Site, Cleveland, Ohio, United States
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04280328
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.